• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial

byAlex XiangandSimon Pan
October 20, 2025
in Cardiology, Chronic Disease, Imaging and Intervention, Pharma
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. At one month, ticagrelor was not superior to twice-daily clopidogrel in reducing major adverse cardiovascular events (MACEs) in adult patients receiving primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).

Evidence Rating Level: 1 (Excellent)

The highest risk period for MACEs after primary PCI for STEMI is in the first month. Both ticagrelor and double-dose clopidogrel have been shown to improve patient outcomes after acute coronary syndrome. However, no study has compared these strategies in the early high-risk post-STEMI period. This double-blind, randomized controlled trial analyzed whether ticagrelor is superior to twice-daily clopidogrel in reducing 30-day MACEs in adult patients with STEMI undergoing primary PCI. 2,201 patients (mean[SD] age, 54.8 ± 10.1 years; 87.3% male) to receive either clopidogrel 75 mg twice daily or ticagrelor 90 mg twice daily for one month. All patients received aspirin 75 mg daily. At 7 and 14 days, there was a significantly lower incidence of MACEs in patients receiving ticagrelor ((HR: 0.15; 95% CI: 0.04-0.5; P = 0.002) and (HR: 0.46; 95% CI: 0.23-0.91; P = 0.02), respectively), although these differences were no longer statistically significant at 30 days (HR: 0.75; 95% CI: 0.44-1.27; P = 0.28; absolute risk difference: -0.7%; 95% CI: -2.05 to 0.60). The ticagrelor group had a higher risk of any bleeding event (HR: 2.08; 95% CI: 1.10-3.93), as defined by the Bleeding Academic Research Consortium (BARC) criteria, but there was no significant difference in the incidence of clinically significant or major bleeding (BARC 2, 3, 5; HR: 1.50; 95% CI: 0.42-5.31). Overall, ticagrelor was not superior to twice-daily clopidogrel in reducing MACEs at 1 month after primary PCI. However, further studies with larger cohorts are warranted as MACEs were significantly reduced in patients receiving ticagrelor at 7 and 14 days.

Click here to read this study in The Journal of the American College of Cardiology

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

2 Minute Medicine Rewind October 20, 2025

Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community‐Based Cohort Study

2 Minute Medicine Rewind October 13, 2025

Tags: #cardiologyclopidogrelPCISTEMITicagrelor
Previous Post

Work effort and time expenditure of primary care physicians

RelatedReports

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Weekly Rewinds

2 Minute Medicine Rewind October 20, 2025

October 20, 2025
Few older adolescents meet recommended levels of physical activity
Cardiology

Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community‐Based Cohort Study

October 14, 2025
Weekly Rewinds

2 Minute Medicine Rewind October 13, 2025

October 13, 2025
Weekly Rewinds

2 Minute Medicine Rewind September 15, 2025

September 15, 2025

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial
  • Work effort and time expenditure of primary care physicians
  • Increasing cancer incidence rates in younger and older adults worldwide
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.